OverviewSuggest Edit

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
TypePublic
Founded2003
HQMilton, GB
Websitesummitplc.com
Employee Ratings0

Latest Updates

Employees (est.) (Oct 2017)44
Revenue (FY, 2018)£25.4 M(+1004%)

Key People/Management at Summit Therapeutics

Glyn Edwards

Glyn Edwards

CEO
Erik Ostrowski

Erik Ostrowski

CFO
David Roblin

David Roblin

Chief Operating Officer, Chief Medical Officer and President of R&D
Daniel Elger

Daniel Elger

Chief Commercial Officer and SVP, R&D
Richard Vickers

Richard Vickers

Chief Scientific Officer and SVP, Antimicrobials
Dave Powell

Dave Powell

Head of Research and SVP
Show more

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton and Cambridge
Milton, GB (HQ)
Park House Park Dr 85b
Cambridge, US
One Broadway, 1 Broadway
Show all (2)
Report incorrect company information

Summit Therapeutics Financials and Metrics

Summit Therapeutics Revenue

Summit Therapeutics's revenue was reported to be £25.42 m in FY, 2018
GBP

Revenue (FY, 2018)

25.4m

Net income (FY, 2018)

(7.1m)

EBITDA (FY, 2018)

(12.6m)

EBIT (FY, 2018)

(12.8m)

Cash (31-Jan-2018)

20.1m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

113.0k531.0k1.0m3.0m1.8m189.0k763.0k1.8m1.8m1.8m2.1m1.5m2.3m25.4m

Revenue growth, %

16%(32%)

Cost of goods sold

279.0k233.0k304.0k1.6m1.1m

Gross profit

(166.0k)298.0k730.0k1.4m773.0k
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.2m12.6m18.3m10.1m2.7m6.1m3.3m2.1m3.4m2.0m11.3m16.3m28.1m20.1m

Accounts Receivable

40.0k129.0k283.0k189.0k651.0k41.0k32.0k47.0k51.0k

Inventories

27.0k187.0k337.0k391.0k

Current Assets

14.3m13.2m19.6m12.7m5.4m6.6m3.7m2.6m4.2m3.1m15.2m20.8m33.3m35.9m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(499.0k)(995.0k)(3.0m)(10.1m)(22.4m)(6.2m)(4.7m)(2.7m)(4.2m)(6.1m)(11.4m)(20.1m)(21.4m)(7.1m)

Cash From Operating Activities

185.0k1.4m3.2m8.1m(10.1m)(3.1m)(2.7m)(2.4m)(3.2m)(5.9m)(11.3m)(17.2m)12.1m(14.7m)

Cash From Financing Activities

14.1m757.0k9.9m633.0k3.6m5.0m14.0k1.4m4.6m4.5m20.5m22.1m413.0k13.9m

Net Change in Cash

282.0k678.0k2.2m8.2m(7.4m)3.4m(2.8m)(1.2m)1.3m(1.3m)9.2m4.9m12.5m(6.0m)
GBPY, 2018

Revenue/Employee

577.7k

Financial Leverage

5.5 x
Show all financial metrics
Report incorrect company information

Summit Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Summit Therapeutics News and Updates

Summit Therapeutics to Participate in Upcoming Investor Events

Summit Therapeutics plc  (‘Summit’ or the ’Company’)

Summit Therapeutics to Participate in Upcoming Investor Conferences

Summit Therapeutics plc  (‘Summit’ or the ’Company’)

Summit Therapeutics Joins Antimicrobials Working Group

WASHINGTON, July 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations....

Summit Therapeutics to stop developing muscle-wasting disorder drug

June 27 (Reuters) - Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.
Show more
Report incorrect company information

Summit Therapeutics Frequently Asked Questions

  • When was Summit Therapeutics founded?

    Summit Therapeutics was founded in 2003.

  • Who are Summit Therapeutics key executives?

    Summit Therapeutics's key executives are Glyn Edwards, Erik Ostrowski and David Roblin.

  • How many employees does Summit Therapeutics have?

    Summit Therapeutics has 44 employees.

  • What is Summit Therapeutics revenue?

    Latest Summit Therapeutics annual revenue is £25.4 m.

  • What is Summit Therapeutics revenue per employee?

    Latest Summit Therapeutics revenue per employee is £577.7 k.

  • Who are Summit Therapeutics competitors?

    Competitors of Summit Therapeutics include STERIS, BioScrip and Perrigo.

  • Where is Summit Therapeutics headquarters?

    Summit Therapeutics headquarters is located at Park House Park Dr 85b, Milton.

  • Where are Summit Therapeutics offices?

    Summit Therapeutics has offices in Milton and Cambridge.

  • How many offices does Summit Therapeutics have?

    Summit Therapeutics has 2 offices.